Akeso, Inc.announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome sub...
Culture Biosciences, an expert in cloud-connected bioreactor technology, and Cytiva, a Danaher company and a leader in the life sciences industry, ...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, announced Novasign and Repligen have entered ...
Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results fro...
WuXi XDC Cayman Inc., a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announ...
As advanced modalities like mRNA and viral vectors reshape the biomanufacturing landscape, Cytiva is scaling innovation to meet evolving demands. In this e...
MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, has joined efforts with...
BriaCell Therapeutics Corp. a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned s...
Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), and Antheia, the pharmaceutical ingredient man...
Bio Usawa, a pioneering private biotechnology company committed to developing and manufacturing affordable, high‑quality monoclonal antibody therapies ...
Bio Usawa Biotechnology Ltd. (Bio Usawa) and ServareGMP (Servare) announced a strategic partnership to establish advanced monoclonal antibody manufacturi...
4TEEN4 Pharmaceuticals GmbH announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal anti...
© 2025 Biopharma Boardroom. All Rights Reserved.
